Survival from prostate cancer in England and Wales up to 2001

por Clarke, N W
Publicado 2008

Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells

por Tawadros, T, Brown, M D, Hart, C A, Clarke, N W
Publicado 2012

Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process

por Hart, C A, Brown, M, Bagley, S, Sharrard, M, Clarke, N W
Publicado 2005

Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study.

por Clarke, N. W., Holbrook, I. B., McClure, J., George, N. J.
Publicado 1991

Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs

por Brown, M D, Hart, C A, Gazi, E, Bagley, S, Clarke, N W
Publicado 2006

Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer

por Brown, M, Roulson, J-A, Hart, C A, Tawadros, T, Clarke, N W
Publicado 2014

Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines

por Maddineni, S B, Sangar, V K, Hendry, J H, Margison, G P, Clarke, N W
Publicado 2005

An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines

por Sangar, V K, Cowan, R, Margison, G P, Hendry, J H, Clarke, N W
Publicado 2004

MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer

por Cannistraci, A., Hascoet, P., Ali, A., Mundra, P., Clarke, N. W., Pavet, V., Marais, R.
Publicado 2022

Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies

por Hart, C A, Scott, L J, Bagley, S, Bryden, A A G, Clarke, N W, Lang, S H
Publicado 2002

FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer

por Baker, M J, Gazi, E, Brown, M D, Shanks, J H, Gardner, P, Clarke, N W
Publicado 2008

Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases

por Bryden, A A G, Hoyland, J A, Freemont, A J, Clarke, N W, George, N J R
Publicado 2002

Optimization of the reverse transcriptase polymerase chain reaction for the detection of circulating prostate cells

por McIntyre, I G, Spreckley, K, Clarke, R B, Anderson, E, Clarke, N W, George, N J R
Publicado 2000

Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasion

por Scott, L J, Clarke, N W, George, N J R, Shanks, J H, Testa, N G, Lang, S H
Publicado 2001

Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy

por Griffiths, R W, Gilham, D E, Dangoor, A, Ramani, V, Clarke, N W, Stern, P L, Hawkins, R E
Publicado 2005

Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation

por Parry, M. G., Cowling, T. E., Sujenthiran, A., Nossiter, J., Berry, B., Cathcart, P., Aggarwal, A., Payne, H., van der Meulen, J., Clarke, N. W., Gnanapragasam, V. J.
Publicado 2020

Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study

por Larkin, S E T, Johnston, H E, Jackson, T R, Jamieson, D G, Roumeliotis, T I, Mockridge, C I, Michael, A, Manousopoulou, A, Papachristou, E K, Brown, M D, Clarke, N W, Pandha, H, Aukim-Hastie, C L, Cragg, M S, Garbis, S D, Townsend, P A
Publicado 2016

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis

por Vale, C L, Fisher, D J, White, I R, Carpenter, J R, Burdett, S, Clarke, N W, Fizazi, K, Gravis, G, James, N D, Mason, M D, Parmar, M K B, Rydzewska, L H, Sweeney, C J, Spears, M R, Sydes, M R, Tierney, J F
Publicado 2018

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

por Sydes, M R, Spears, M R, Mason, M D, Clarke, N W, Dearnaley, D P, de Bono, J S, Attard, G, Chowdhury, S, Cross, W, Gillessen, S, Malik, Z I, Jones, R, Parker, C C, Ritchie, A W S, Russell, J M, Millman, R, Matheson, D, Amos, C, Gilson, C, Birtle, A, Brock, S, Capaldi, L, Chakraborti, P, Choudhury, A, Evans, L, Ford, D, Gale, J, Gibbs, S, Gilbert, D C, Hughes, R, McLaren, D, Lester, J F, Nikapota, A, O’Sullivan, J, Parikh, O, Peedell, C, Protheroe, A, Rudman, S M, Shaffer, R, Sheehan, D, Simms, M, Srihari, N, Strebel, R, Sundar, S, Tolan, S, Tsang, D, Varughese, M, Wagstaff, J, Parmar, M K B, James, N D
Publicado 2018

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

por Clarke, N W, Ali, A, Ingleby, F C, Hoyle, A, Amos, C L, Attard, G, Brawley, C D, Calvert, J, Chowdhury, S, Cook, A, Cross, W, Dearnaley, D P, Douis, H, Gilbert, D, Gillessen, S, Jones, R J, Langley, R E, MacNair, A, Malik, Z, Mason, M D, Matheson, D, Millman, R, Parker, C C, Ritchie, A W S, Rush, H, Russell, J M, Brown, J, Beesley, S, Birtle, A, Capaldi, L, Gale, J, Gibbs, S, Lydon, A, Nikapota, A, Omlin, A, O'Sullivan, J M, Parikh, O, Protheroe, A, Rudman, S, Srihari, N N, Simms, M, Tanguay, J S, Tolan, S, Wagstaff, J, Wallace, J, Wylie, J, Zarkar, A, Sydes, M R, Parmar, M K B, James, N D
Publicado 2019